Document is current
Any future updates will be listed below
-
Authors
Liu, Xiaolei
De la Cruz, Ester
Gu, Xiaowu https://orcid.org/0000-0003-2266-5516
Balint, Laszlo https://orcid.org/0000-0002-3142-4071
Oxendine-Burns, Michael https://orcid.org/0000-0002-8054-0757
Terrones, Tamara
Ma, Wanshu
Kuo, Hui-Hsuan https://orcid.org/0000-0001-8266-7105
Lantz, Connor https://orcid.org/0000-0003-3317-6486
Bansal, Trisha
Thorp, Edward https://orcid.org/0000-0003-1387-7058
Burridge, Paul https://orcid.org/0000-0001-9616-0006
Jakus, Zoltán https://orcid.org/0000-0002-6304-2369
Herz, Joachim
Cleaver, Ondine
Torres, Miguel https://orcid.org/0000-0003-0906-4767
Oliver, Guillermo https://orcid.org/0000-0003-3984-7615
- License Information
-
More Information
Article History
Received: 13 June 2019
Accepted: 7 October 2020
First Online: 9 December 2020
Competing interests
: J.H. is a shareholder of Reelin Therapeutics and a co-inventor on a pending US patent application filed by his institution (UT Southwestern; application number 15/763,047 and publication number 20180273637, title “Methods and Compositions for Treatment of Atherosclerosis”; Inventors: J.H., Y. Ding, X. Xian, L. Huang, C. Mineo, P. Shaul and L. Calvier). This patent application covers no aspects of the current manuscript. Findings regarding the potential applications and methods for using RELN to treat cardiac diseases are the subject of provisional patent application (US63/091,558) owned by Northwestern University and list X.L. and G.O. as inventors. All other authors declare no competing interests.
